Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Exercise / conversionCommon Stock | 304 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000089 · wk-form4_1747692404.xml · nonDerivative · entry 2 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
GrantCommon Stock | 870 | $19.30 | $16,791.00 |
DisclosureSEC source: 0001438133-25-000089 · wk-form4_1747692404.xml · nonDerivative · entry 1 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,004 F1 · acquired: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2024, through May 15, 2025. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · derivative · entry 13 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,774 Underlying: Common Stock · 4,387 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan. F9 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F12 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F12 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · derivative · entry 12 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,012 Underlying: Common Stock · 1,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F9 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F10 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F10 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 474 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · derivative · entry 11 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 474 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 162 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · derivative · entry 10 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F5 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. F5 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Tax withholdingCommon Stock | 1,255 | $22.70 | $28,488.50 |
DisclosureSEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · nonDerivative · entry 9 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,206 F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionCommon Stock | 4,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · nonDerivative · entry 8 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Tax withholdingCommon Stock | 430 | $22.70 | $9,761.00 |
DisclosureSEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · nonDerivative · entry 7 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,074 F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionCommon Stock | 1,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · nonDerivative · entry 6 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Tax withholdingCommon Stock | 136 | $22.70 | $3,087.20 |
DisclosureSEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · nonDerivative · entry 5 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,001 F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionCommon Stock | 474 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · nonDerivative · entry 4 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Tax withholdingCommon Stock | 47 | $22.70 | $1,066.90 |
DisclosureSEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · nonDerivative · entry 3 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,663 F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionCommon Stock | 162 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · nonDerivative · entry 2 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
GrantCommon Stock | 1,359 | $15.64 | $21,254.76 |
DisclosureSEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · nonDerivative · entry 1 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,548 F1 · acquired: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2024, through May 15, 2025. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,589 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · derivative · entry 10 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,179 Underlying: Common Stock · 3,589 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F10 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F10 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · derivative · entry 9 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,748 Underlying: Common Stock · 1,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F7 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F8 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F8 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 596 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · derivative · entry 8 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 596 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 25, 2022 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F5 · derivative.exercise_date: RSU vest as to thiry-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F5 · derivative.expiration_date: RSU vest as to thiry-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Carpenter RickChief Technology Officer
|
Tax withholdingCommon Stock | 1,285 | $22.70 | $29,169.50 |
DisclosureSEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · nonDerivative · entry 7 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,020 F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionCommon Stock | 3,589 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · nonDerivative · entry 6 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Carpenter RickChief Technology Officer
|
Tax withholdingCommon Stock | 515 | $22.70 | $11,690.50 |
DisclosureSEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · nonDerivative · entry 5 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,716 F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionCommon Stock | 1,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · nonDerivative · entry 4 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Carpenter RickChief Technology Officer
|
Tax withholdingCommon Stock | 214 | $22.70 | $4,857.80 |
DisclosureSEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · nonDerivative · entry 3 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,794 F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionCommon Stock | 596 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · nonDerivative · entry 2 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Carpenter RickChief Technology Officer
|
GrantCommon Stock | 1,020 | $15.64 | $15,952.80 |
DisclosureSEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · nonDerivative · entry 1 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,412 F1 · acquired: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2024, through May 15, 2025. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 23,929 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · derivative · entry 13 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,858 Underlying: Common Stock · 23,929 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan. F9 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F12 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F12 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 5,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · derivative · entry 12 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,886 Underlying: Common Stock · 5,472 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F9 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F10 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F10 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · derivative · entry 11 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,236 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan. F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 792 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · derivative · entry 10 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 792 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F5 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. F5 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Tax withholdingCommon Stock | 12,152 | $22.70 | $275,850.40 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 9 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,327 F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionCommon Stock | 23,929 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 8 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Tax withholdingCommon Stock | 2,779 | $22.70 | $63,083.30 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 7 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,550 F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionCommon Stock | 5,472 | $22.70 | $124,214.40 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 6 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Tax withholdingCommon Stock | 1,136 | $22.70 | $25,787.20 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 5 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,857 F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionCommon Stock | 2,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Tax withholdingCommon Stock | 403 | $22.70 | $9,148.10 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,757 F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionCommon Stock | 792 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
GrantCommon Stock | 1,359 | $15.64 | $21,254.76 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,368 F1 · acquired: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2024, through May 15, 2025. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:05 UTC |
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
|
GrantCommon Stock | 171 | $19.30 | $3,300.30 |
DisclosureSEC source: 0001438133-25-000084 · wk-form4_1747692340.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,709 F1 · acquired: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2024, through May 15, 2025. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:12 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000046 · wk-form4_1742415145.xml · derivative · entry 3 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,902 Underlying: Common Stock · 7,415 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on December 15, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:12 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Tax withholdingCommon Stock | 2,739 | $19.17 | $52,506.63 |
DisclosureSEC source: 0001438133-25-000046 · wk-form4_1742415145.xml · nonDerivative · entry 2 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,134 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:12 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Exercise / conversionCommon Stock | 7,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000046 · wk-form4_1742415145.xml · nonDerivative · entry 1 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:12 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 406 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000045 · wk-form4_1742415136.xml · derivative · entry 3 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,218 Underlying: Common Stock · 406 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on December 15, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F4 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 12/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 12/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:12 UTC |
Carpenter RickChief Technology Officer
|
Tax withholdingCommon Stock | 146 | $19.17 | $2,798.82 |
DisclosureSEC source: 0001438133-25-000045 · wk-form4_1742415136.xml · nonDerivative · entry 2 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,392 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:12 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionCommon Stock | 406 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000045 · wk-form4_1742415136.xml · nonDerivative · entry 1 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 22:06 UTC |
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
|
PurchaseCommon Stock | 10,538 | $18.12 | $190,966.47 |
DisclosureSEC source: 0001438133-25-000042 · wk-form4_1741730755.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,538 F1 · price: This transaction was executed in multiple trades at prices ranging from $18.115 to $18.13 per share. The reported price reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:15 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Exercise / conversionPerformance Stock Unit · Derivative | 5,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000038 · wk-form4_1740694524.xml · derivative · entry 7 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,523 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan. F4 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. F4 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. F4 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:15 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Exercise / conversionPerformance Stock Unit · Derivative | 1,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000038 · wk-form4_1740694524.xml · derivative · entry 6 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,380 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F4 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. F4 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. F4 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:15 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Tax withholdingCommon Stock | 3,009 | $33.34 | $100,320.06 |
DisclosureSEC source: 0001438133-25-000038 · wk-form4_1740694524.xml · nonDerivative · entry 4 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,023 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of performance stock units (PSU). No shares were sold. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:15 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Exercise / conversionCommon Stock | 5,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000038 · wk-form4_1740694524.xml · nonDerivative · entry 3 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.